A5088321973- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Antifungal resistance and susceptibility
- Research on Leishmaniasis Studies
- Drug-Induced Ocular Toxicity
- Cancer-related Molecular Pathways
- Microbial Natural Products and Biosynthesis
- Peptidase Inhibition and Analysis
- Cell death mechanisms and regulation
- Genomics and Phylogenetic Studies
- Chronic Myeloid Leukemia Treatments
- HER2/EGFR in Cancer Research
- Neuroblastoma Research and Treatments
- Ubiquitin and proteasome pathways
Cancer Institute of New South Wales
2023-2025
UNSW Sydney
2023-2025
University of Otago
2022
Children's Cancer Institute Australia
2022
Antibody-drug conjugates (ADCs) combining monoclonal antibodies with cytotoxic payloads are a rapidly emerging class of immune-based therapeutics the potential to improve treatment cancer, including children relapse/refractory acute lymphoblastic leukemia (ALL). CD123, α subunit interleukin-3 receptor, is overexpressed in ALL and therapeutic target. Here, we show that pivekimab sunirine (PVEK), recently developed ADC comprising CD123-targeting antibody, G4723A, payload, DGN549, was highly...
Abstract Background Acute lymphoblastic leukemia (ALL) remains one of the most common causes cancer‐related mortality in children. Phosphoinositide 3‐kinases (PI3Ks) are a family lipid kinases, and aberrations PI3K pathway associated with several hematological malignancies, including ALL. Duvelisib (Copiktra) is an orally available, small molecule dual inhibitor PI3Kδ PI3Kγ, that Food Drug Administration (FDA) approved for treatment relapsed/refractory chronic lymphocytic lymphoma. Here, we...
Abstract Introduction: Children diagnosed with acute lymphoblastic leukemia (ALL) experience ~90% likelihood of cure. However, the outcome for high-risk ALL and children who relapse remains poor. Receptor tyrosine kinase like orphan 1 receptor (ROR1) is a cell surface antigen primarily expressed in embryonic tissue, but also overexpressed hematological malignancies. UC961 humanized IgG monoclonal antibody high affinity ROR1. MK-2140 (Zilovertamab vedotin/VLS-101) VLS-211 are antibody-drug...
Abstract Introduction: Over 70% of infants with acute lymphoblastic leukemia (ALL) present mixed lineage (MLL1/KMT2A) gene rearrangements (MLL-r ALL), which is associated poor prognosis. MLL-r encodes oncogenic fusion proteins that cause aberrant chromatin histone methylation and leukemic transformation hematopoietic progenitors. A characteristic high expression the FLT3 gene. Menin critical for by MLL proteins. VTP-50469, preclinical precursor revumenib (SNDX-5613), a potent selective small...
<ns3:p><ns3:bold>Background: </ns3:bold>Spiroleucettadine is an alkaloid originally derived from the yellow <ns3:italic>Leucetta </ns3:italic>sea sponge. Spiroleucettadine has previously been shown to inhibit growth of various cancer cell lines and a high anti-proliferative activity against non-small lung line (H522). The mediators these effects have not determined. Therefore, in this study we measured changes death proliferation their immediate protein response spiroleucettadine, toward aim...